Bivalent inhibition of human β-tryptase

Chemistry and Biology

Volumn 8, Issue 4, 2001, Pages 313-327

  Schaschke, Norbert ^a   Matschiner, Gabriele ^b   Zettl, Frank ^b   Marquardt, Ulf ^a   Bergner, Andreas ^a   Bode, Wolfram ^a   Sommerhoff, Christian P ^b   Moroder, Luis ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cyclodextrin; Tryptase; Bivalent inhibitor; Circular dichroism; X ray analysis

Indexed keywords

BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; TRYPSIN; TRYPTASE;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; DRUG ANTAGONISM; DRUG DESIGN; ENZYME SPECIFICITY; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; TEMPERATURE; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

BETA-CYCLODEXTRINS; BINDING SITES; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; CYCLODEXTRINS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN STRUCTURE, TERTIARY; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY; TEMPERATURE; THERMODYNAMICS; THROMBIN; TRYPSIN; TRYPTASES;

EID: 0035033274     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(01)00011-4     Document Type: Article

References (59)

1. Mammen M., Choi S.-K., Whitesides G.M. Polyvalent interactions in biological systems - Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. Engl. 37:1998;2755-2794.
2. Kiessling L.L., Pohl N.L. Strength in numbers: non-natural polyvalent carbohydrate derivatives. Chem. Biol. 3:1996;71-77.
3. Lee Y.C., Lee R.T. Carbohydrate-protein interactions: basis of glycobiology. Acc. Chem. Res. 28:1995;321-327.
4. Matrosovich M.N. Towards the development of antimicrobial drugs acting by inhibition of pathogen attachment to host cells: a need for polyvalency. FEBS Lett. 252:1989;1-4.
5. Spaltenstein A., Whitesides G.M. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus. J. Am. Chem. Soc. 113:1991;686-687.
6. Glick G.D., Toogood P.L., Wiley D.C., Skehel J.J., Knowles J.R. Ligand recognition by influenza virus. The binding of bivalent sialosides. J. Biol. Chem. 266:1991;23660-23669.
7. Fan E., Zhang Z., Minke W.E., Hou Z., Verlinde C.L.M.J., Hol W.G.J. High-affinity pentavalent ligands of Escherichia coli heat-labile enterotoxin by modular structure-based design. J. Am. Chem. Soc. 122:2000;2663-2664.
8. Carrithers M.G., Lerner M.R. Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem. Biol. 3:1996;537-542.
9. Kramer R.H., Karpen J.W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature. 395:1998;710-713.
10. Cheronis J.C., Whalley E.T., Nguyen K.T., Eubanks S.R., Allen L.G., Duggan M.J., Loy S.D., Bonham K.A., Blodgett J.K. A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J. Med. Chem. 35:1992;1563-1572.
11. Pang Y.-P., Quiram P., Jelacic T., Hong F., Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 271:1996;23646-23649.
12. Profit A.A., Lee T.R., Lawrence D.S. Bivalent inhibitors of protein tyrosine kinases. J. Am. Chem. Soc. 121:1999;280-283.
13. Dodt J. Anticoagulatory substances of bloodsucking animals - from hirudin to hirudin mimetics. Angew. Chem. Int. Ed. Engl. 34:1995;867-880.
14. 1′ with arginyl ketomethylene isosteres. J. Med. Chem. 42:1999;3109-3115.
15. Steinmetzer T., Renatus M., Kunzel S., Eichinger A., Bode W., Wikstrom P., Hauptmann J., Stürzebecher J. Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines. Eur. J. Biochem. 265:1999;598-605.
16. Crothers D.M., Metzger H. The influence of polyvalency on the binding properties of antibodies. Immunochemistry. 9:1972;341-357.
17. Rappaport H.P. Evaluation of group contributions to ligand binding. J. Theor. Biol. 79:1979;157-165.
18. Jencks W.P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA. 78:1981;4046-4050.
19. Rao J., Lahiri J., Isaacs L., Weis R.M., Whitesides G.M. A trivalent system from vancomycin·D-Ala-D-Ala with higher affinity than avidin·biotin. Science. 280:1998;708-711.
20. Rao J., Lahiri J., Weis R.M., Whitesides G.M. Design, synthesis, and characterization of a high-affinity trivalent system derived from vancomycin and L-Lys-D-Ala-D-Ala. J. Am. Chem. Soc. 122:2000;2698-2710.
21. Rydel T.J., Ravichandran K.G., Tulinsky A., Bode W., Huber R., Roitsch C., Fenton II J.W. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 249:1990;277-280.
22. Groll M., Ditzel L., Löwe J., Stock D., Bochtler M., Bartunik H.D., Huber R. Structure of the 20S proteasome from yeast at 2.4 Å resolution. Nature. 386:1997;463-471.
23. Barbosa Pereira P.J., Bergner A., Macedo-Ribeiro S., Huber R., Matschiner G., Fritz H., Sommerhoff C.P., Bode W. Human β-tryptase is a ring-like tetramer with active sites facing a central pore. Nature. 392:1998;306-311.
24. Sommerhoff C.P., Bode W., Barbosa Pereira P.J., Stubbs M.T., Stürzebecher J., Piechottka G.P., Matschiner G., Bergner A. The structure of the human βII-tryptase tetramer: fo(u)r better or worse. Proc. Natl. Acad. Sci. USA. 96:1999;10984-10991.
25. Loidl G., Groll M., Musiol H.-J., Huber R., Moroder L. Bivalency as a principle for proteasome inhibition. Proc. Natl. Acad. Sci. USA. 96:1999;5418-5422.
26. Loidl G., Musiol H.-J., Groll M., Huber R., Moroder L. Synthesis of bivalent inhibitors of eucaryotic proteasomes. J. Peptide Sci. 6:2000;36-46.
27. Sommerhoff C.P., Bode W., Matschiner G., Bergner A., Fritz H. The human mast cell tryptase tetramer: a fascinating riddle solved by structure. Biochim. Biophys. Acta. 1477:2000;75-89.
28. Schaschke N., Musiol H.-J., Assfalg-Machleidt I., Machleidt W., Rudolph-Böhner S., Moroder L. Cyclodextrins as templates for the presentation of protease inhibitors. FEBS Lett. 391:1996;297-301.
29. Schaschke N., Fiori S., Weyher E., Escrieut C., Fourmy D., Müller G., Moroder L. Cyclodextrin as carrier of peptide hormones. Conformational and biological properties of β-cyclodextrin/gastrin constructs. J. Am. Chem. Soc. 120:1998;7030-7038.
30. Schaschke N., Assfalg-Machleidt I., Machleidt W., Laßleben T., Sommerhoff C.P., Moroder L. β-Cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells. Bioorg. Med. Chem. Lett. 10:2000;677-680.
31. Tabushi I., Yamamura K., Nabeshima T. Characterization of regiospecific A,C- and A,D-disulfonate capping of β-cyclodextrin. Capping as an efficient production technique. J. Am. Chem. Soc. 106:1984;5267-5270.
32. ®: a new peptide coupling reagent devoid of toxic by-product. Tetrahedron Lett. 31:1990;205-208.
33. Schwartz L.B., Bradford T.R. Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer. J. Biol. Chem. 261:1986;7372-7379.
34. Alter S.C., Metcalf D.D., Bradford T.R., Schwartz L.B. Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysacchrides. Biochem. J. 248:1987;821-827.
35. Goldstein S.M., Leong J., Schwartz L.B., Cooke D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J. Immunol. 148:1992;2475-2482.
36. Lindstedt K.A., Kokkonen J.O., Kovanen P.T. Regulation of the activity of secreted human lung mast cell tryptase by mast cell proteoglycans. Biochim. Biophys. Acta. 1425:1998;617-627.
37. Addington K.A., Johnson D.A. Inactivation of human lung tryptase: evidence for a re-activable tetrameric intermediate and active monomers. Biochemistry. 35:1996;13511-13518.
38. Kozik A., Potempa J., Travis J. Spontaneous inactivation of human lung tryptase as probed by size-exclusion chromatography and chemical cross-linking: dissociation of active tetrameric enzyme into inactive monomers is the primary event of the entire process. Biochim. Biophys. Acta. 1385:1998;139-148.
39. Huber R., Bode W. Structural basis of the activation and action of trypsin. Acc. Chem. Res. 11:1978;114-122.
40. Bode W. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-trypsinogen. J. Mol. Biol. 127:1979;357-374.
41. C.R. Cantor, S.N. Timasheff, Optical spectroscopy of proteins, in: H. Neurath, R.L. Hill (Eds.), The Proteins, 3rd edn., Vol. 5, Academic Press, New York, 1982, pp. 145-306.
42. Grishina I.B., Woody R.W. Contributions of tryptophan side chains to the circular dichroism of globular proteins: Exciton couplets and coupled oscillators. Faraday Discuss. 99:1994;245-262.
43. Johnson D.A., Barton G.J. Mast cell tryptases: examination of unusual characteristics by multiple sequence alignment and molecular modeling. Protein Sci. 1:1992;370-377.
44. Schwartz L.B., Bradford T.R., Lee D.C., Chlebowski J.F. Immunologic and physicochemical evidence for conformational changes occuring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase. J. Immunol. 144:1990;2304-2311.
45. Schechter N.M., Eng G.Y., Selwood T., McCaslin D.R. Structural changes associated with the spontaneous inactivation of the serine proteinase human tryptase. Biochemistry. 34:1995;10628-10638.
46. C.P. Sommerhoff, Dog mast cell proteinases in models of airway secretion, bronchoconstriction, cutaneous vascular permeability, and tissue fibrosis, in: G.H. Caughey (Ed.), Mast Cell Proteases in Immunology and Biology, Marcel Dekker, New York, 1995, pp. 145-167.
47. Caughey G.H. Of mites and men - trypsin-like proteases in the lungs. Am. J. Respir. Cell Mol. Biol. 16:1997;621-628.
48. Johnson P.R., Ammit A.J., Carlin S.M., Armour C.L., Caughey G.H., Black J.L. Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus. Eur. Respir. J. 10:1997;38-43.
49. Rice K.D., Tanaka R.D., Katz B.A., Numerof R.P., Moore W.R. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr. Pharm. Des. 4:1998;381-396.
50. De Sanctis G.T., Merchant M., Beier D.R., Dredge R.D., Grobholz J.K., Martin T.R., Lander E.S., Drazen J.M. Quantitative locus analysis of airway hyperresponsiveness in A/J and C75BL/6J mice. Nature Genet. 11:1995;150-154.
51. Hunt J.E., Stevens R.L., Austen K.F., Zhang J., Xia Z., Ghildyal N. Natural distribution of the mouse mast cell protease 7 gene in the C57BL/6 mouse. J. Biol Chem. 271:1996;2851-2855.
52. Stürzebecher J., Prasa D., Sommerhoff C.P. Inhibition of mast cell tryptase by benzamidine derivatives. Biol. Chem. Hoppe-Seyler. 373:1992;1025-1030.
53. Caughey G.H., Raymond W.W., Bacci E., Lombardy R.J., Tidwell R.R. Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases. J. Pharmacol. Exp. Ther. 264:1993;676-682.
54. Burgess L.E., Newhouse B.J., Ibrahim P., Rizzi J., Kashem M.A., Hartman A., Brandhuber B.J., Wright C.D., Thomson D.S., Vigers G.P.A., Koch K. Potent selective nonpeptidic inhibitors of human lung tryptase. Proc. Natl. Acad. Sci. USA. 96:1999;8348-8352.
55. Ono S., Kuwahara S., Takeuchi M., Sakashita H., Naito Y., Kondo T. Synthesis and evaluation of amidinobezofuran derivatives as tryptase inhibitors. Bioorg. Med. Chem. Lett. 9:1999;3285-3290.
56. Rice K.D., Gangloff A.R., Kuo E.Y.-L., Dener J.M., Wang V.R., Lum R., Newcomb W.S., Havel C., Putnam D., Cregar L., Wong M., Warne R.L. Dibasic inhibitors of human mast cell tryptase. Part 1: Synthesis and optimization of a novel class of inhibitors. Bioorg. Med. Chem. Lett. 10:2000;2357-2360.
57. Rice K.D., Wang V.R., Gangloff A.R., Kuo E.Y.-L., Dener J.M., Newcomb W.S., Young W.B., Putnam D., Cregar L., Wong M., Simpson P.J. Dibasic inhibitors of human mast cell tryptase. Part 2: Structure-activity relationships and requirements for potent activity. Bioorg. Med. Chem. Lett. 10:2000;2361-2366.
58. Sommerhoff C.P., Söllner C., Mentele R., Piechottka G.P., Auerswald E.A., Fritz H. A Kazal-type inhibitor of human mast cell tryptase: Isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis. Biol. Chem. 375:1994;685-694.
59. Morrison J.F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta. 185:1969;269-286.